iRhythm Q3 revenue $103.9M (+21.6% YoY); cuts FY22 revenue guidance to $407-411M

iRhythm Holdings, Inc.

2022-Q3 EPS reported -$3.22 revenue$298,304,000

Revenue $103.9M (+21.6% YoY); net loss $21.5M ($0.71/sh) vs $23.7M loss in Q3 2021.
Gross margin 68.3%, up 2.6pp from 65.7% in Q3 2021.
FY22 revenue guidance lowered to $407-411M from prior $415-420M (approx 26-27% YoY growth).
Adjusted EBITDA guidance improved to -$10 to -$12M from prior -$12.5 to -$17.5M; adjusted opex guidance $360-365M.
Registration volumes +22% YoY; highest daily registrations at Sept end; cited softness in returned devices persisting into Q4.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

iRhythm Holdings, Inc. reported the three months ended September 30, 2022 results: revenue $103.9 million, net income Net loss for the third quarter of 2022 was $21.5 million, or a loss of $0.71 per share, EPS $0.71 per share. Guidance lowered.

Period: the three months ended September 30, 2022
Revenue: $103.9 million
Net income: Net loss for the third quarter of 2022 was $21.5 million, or a loss of $0.71 per share
EPS: $0.71 per share
Guidance: lowered
Result: reported results

Exact text from the filing

that detect, prevent, and predict disease, today reported financial results for the three months ended September 30, 2022. Third Quarter 2022 Financial Results • Revenue of $103.9 million, a 21.6% increase compared to third quarter 2021 • Gross margin of 68.3%, a 2.6 percentage point improvement compared to third quarter 2021 • Cash, cash equivalents and

View on SEC.gov

Browse all earnings releases →

iRhythm Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001388658-22-000149

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.